RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review
SKU ID : GD-14105526 | Publishing Date : 10-Apr-2019 | No. of pages : 57
Detailed TOC of RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review
Table of ContentsTable of Contents
List of Tables
List of Figures
Section 1 - About the Company
RegenxBio Inc - Key Facts
RegenxBio Inc - Key Employees
RegenxBio Inc - Key Employee Biographies
RegenxBio Inc - Major Products and Services
RegenxBio Inc - History
RegenxBio Inc - Company Statement
RegenxBio Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
RegenxBio Inc - Business Description
R&D Overview
RegenxBio Inc - Corporate Strategy
RegenxBio Inc - SWOT Analysis
SWOT Analysis - Overview
RegenxBio Inc - Strengths
RegenxBio Inc - Weaknesses
RegenxBio Inc - Opportunities
RegenxBio Inc - Threats
RegenxBio Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
RegenxBio Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 27, 2019: REGENXBIO reports fourth quarter and full-year 2018 financial results and recent operational highlights
Jan 04, 2019: REGENXBIO reports continued progress across programs in year-end 2018 corporate update
Nov 07, 2018: REGENXBIO reports third quarter 2018 financial and operating results and announces initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS II
Oct 26, 2018: REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2018 Annual Meeting
Oct 04, 2018: REGENXBIO Announces Completion of Dosing of Fourth Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD
Aug 08, 2018: REGENXBIO Announces Proposed Public Offering Of Common Stock
May 29, 2018: REGENXBIO Names Alexandra Glucksmann As Board Director
May 15, 2018: REGENXBIO Joins the Mucopolysaccharidosis Community to Advance Research and Innovation
May 08, 2018: REGENXBIO Reports First Quarter 2018 Financial Results and Recent Operational Highlights
Apr 23, 2018: Groundbreaking Research for Inherited Retinal Diseases Funded by Foundation Fighting Blindness to be Showcased at ARVO
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Figures, Tables and Charts Available in RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review
List of TablesRegenxBio Inc, Key Facts
RegenxBio Inc, Key Employees
RegenxBio Inc, Key Employee Biographies
RegenxBio Inc, Major Products and Services
RegenxBio Inc, History
RegenxBio Inc, Subsidiaries
RegenxBio Inc, Key Competitors
RegenxBio Inc, Ratios based on current share price
RegenxBio Inc, Annual Ratios
RegenxBio Inc, Annual Ratios (Cont...1)
RegenxBio Inc, Interim Ratios
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
RegenxBio Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios List of Figures
RegenxBio Inc, Performance Chart (2014 - 2018)
RegenxBio Inc, Ratio Charts
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
Keyplayers in RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review
UniQure NVSpark Therapeutics Inc
Shire Plc
Sangamo Therapeutics Inc
Regeneron Pharmaceuticals Inc
Kastle Therapeutics LLC
Genzyme Corp
Genentech Inc
bluebird bio Inc
BioMarin Pharmaceutical Inc
Applied Genetic Technologies Corp
Amgen Inc
Aegerion Pharmaceuticals Inc
Abeona Therapeutics Inc